Skip to content
Study details
Enrolling now

Methylphenidate for Epilepsy-related Cognitive Deficits

VA Office of Research and Development
NCT IDNCT04419272ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

226

Study length

about 4.1 years

Ages

18+

Locations

4 sites in FL, MA, NY +1

What this study is about

This trial is testing if methylphenidate, a stimulant medication used to treat ADHD, can help with attention and memory problems in adults who have epilepsy. Participants will be randomly assigned to take either methylphenidate or a placebo (sugar pill) and their cognitive function will be tested at different points during it.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Methylphenidate

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

methylphenidate (CNS stimulant; blocks reuptake of dopamine and norepinephrine)

Drug routes

oral (Disintegrating Oral Tablet)

Endpoints

Secondary: Change in Overall Quality of Life, Following Placebo vs. Methylphenidate, Change in Overall Subjective Quality of Life, Post-Open-Label

Body systems

Neurology